The introduction of Amyloid PET imaging enables in vivo detection of brain beta-amyloid deposition, one of the neuropathological hallmarks of Alzheimer disease. There is increasing evidence in support of the clinical utility of Amyloid PET with major studies demonstrating that Amyloid PET improves diagnostic accuracy, increases diagnostic certainty, and results in therapeutic changes. Appropriate use criteria have been developed by the Amyloid Imaging Taskforce (AIT), to guide clinicians by predefining certain scenarios in which amyloid PET would be justified. In this review we aim to provide a practical guide on how and when to use Amyloid PET based on the available research and our own experience. We discuss three main appropriate indicat...
Introduction: The objective of this study was to assess the usefulness of the appropriate use criter...
Introduction: The objective of this study was to assess the usefulness of the appropriate use criter...
Amyloid imaging is currently introduced to the market for clinical use. We will review the evidence ...
In vivo imaging of brain amyloid using positron emission tomography (PET) scanning is widely used in...
Imaging of amyloid deposition using PET has been available in research studies for 2 decades and has...
Imaging of amyloid deposition using PET has been available in research studies for 2 decades and has...
AbstractAmyloid imaging is currently introduced to the market for clinical use. We will review the e...
Amyloid-positron emission tomography (PET) imaging of the brain detects elevated amyloid-beta (amylo...
Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's ...
Amyloid plaques, along with neurofibrillary tangles, are a neuropathologic hallmark of Alzheimer dis...
Recent development in molecular imaging enables measurement of fibrillar amyloid plaque in Alzheimer...
Introduction and aim: Amyloid PET/CT is an "in vivo" imaging that may radically change management of...
Introduction and aim: Amyloid PET/CT is an "in vivo" imaging that may radically change management of...
AbstractUntil recently, estimation of β-amyloid plaque density as a key element for identifying Alzh...
INTRODUCTION: The objective of this study was to assess the usefulness of the appropriate use criter...
Introduction: The objective of this study was to assess the usefulness of the appropriate use criter...
Introduction: The objective of this study was to assess the usefulness of the appropriate use criter...
Amyloid imaging is currently introduced to the market for clinical use. We will review the evidence ...
In vivo imaging of brain amyloid using positron emission tomography (PET) scanning is widely used in...
Imaging of amyloid deposition using PET has been available in research studies for 2 decades and has...
Imaging of amyloid deposition using PET has been available in research studies for 2 decades and has...
AbstractAmyloid imaging is currently introduced to the market for clinical use. We will review the e...
Amyloid-positron emission tomography (PET) imaging of the brain detects elevated amyloid-beta (amylo...
Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's ...
Amyloid plaques, along with neurofibrillary tangles, are a neuropathologic hallmark of Alzheimer dis...
Recent development in molecular imaging enables measurement of fibrillar amyloid plaque in Alzheimer...
Introduction and aim: Amyloid PET/CT is an "in vivo" imaging that may radically change management of...
Introduction and aim: Amyloid PET/CT is an "in vivo" imaging that may radically change management of...
AbstractUntil recently, estimation of β-amyloid plaque density as a key element for identifying Alzh...
INTRODUCTION: The objective of this study was to assess the usefulness of the appropriate use criter...
Introduction: The objective of this study was to assess the usefulness of the appropriate use criter...
Introduction: The objective of this study was to assess the usefulness of the appropriate use criter...
Amyloid imaging is currently introduced to the market for clinical use. We will review the evidence ...